Adaptive bayesian design for phase i dose-finding trials using a joint model of response and toxicity

Journal of Biopharmaceutical Statistics

Volumn 20, Issue 1, 2010, Pages 125-144

  Wang, Meihua ^a   Day, Roger ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adaptive Bayesian design; Log bivariate normal distribution; Phase I trials; Threshold

Indexed keywords

IMATINIB;

ARTICLE; BAYES THEOREM; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION; TREATMENT RESPONSE;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, STATISTICAL; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 75649131785     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400903280613     Document Type: Article

References (35)

1. Babb, J., Rogatko, A., Zacks, S. (1997). Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 11:1103-1120.
2. Bekele, B., Shen, Y. (2005). A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 61:344-354.
3. Braun, T. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 23:240-256.
4. Bryant, J., Day, R. (1995). Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383.
5. Dragalin, V., Fedorov, V. (2006). Adaptive designs for dose-finding based on efficacy toxicity response. Journal of Statistical Planning and Inference 136(6):1800-1823.
6. Dragalin, V., Fedorov, V., Wu, Y. (2008). Two-stage design for dose-finding that accounts for both efficacy and safety. Statistics in Medicine 27(25):5156-5176.
7. Druker, B., Talpaz, M., Resta, D., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine 344(14):1031-1037.
8. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R. A. (2006). IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine 355(23):2408-2417.
9. Durham, S., Flournoy, N., Rosenberger, W. (1997). A random walk rule for phase I clinical trials. Biometrics 53:745-760.
10. Evans, W., Horner, M., Chu, Y., Kalwinsky, D., Roberts, W. (1991). Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferasedeficient child with acute lymphoblastic leukemia. Journal of Pediatrics 119:985-989.
11. Gasparini, M., Eisele, J. (2000). A curve-free method for phase I clinical trials. Biometrics 56:609-615.
12. Goodman, S., Zahurak, M., Piantadosi, S. (1995). Some practical improvments in the continual reassessment method for phase I studies. Statistics in Medicine 14: 1149-1161.
13. Gooley, T., Martin, P., Fisher, L., Pettinger, M. (1994). Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Controlled Clinical trials 15:450-462.
14. Haines, L., Perevoszkaya, I., Rosenberger, W. (2003). Bayesian optimal designs for phase I clinical trials. Biometrics 59:591-600.
15. Ivanova, A., Montazer-Haghighi, A., Mohanty, S., Durham, S. (2003). Improved up-anddown designs for phase I trials. Statistics in Medicine 22:69-82.
16. Korn, E., Midthune, D., Chen, T., Rubinstein, L., Christian, M., Simon, R. (1994). A comparison of two phase I designs. Statistics in Medicine 13:1799-1806.
17. Lennard, L., Lewis, I., Michelagnoli, M., Lilleyman, J. (1997). Thiopurine methyltransferase deficiency in childhood lymphoblastic leukemia: 6-mercaptopurine dosage strategies. Medical and Pediatric Oncology 29:252-255.
18. Leung, D., Wang, Y. (2001). Isotonic designs for phase I trials. Controlled Clinical Trials 22:126-138.
19. Loke, Y., Tan, S., Cai, Y., Machin, D. (2006). A Bayesian dose finding design for dual endpoint phase I trials. Statistics in Medicine 25:3-22.
20. Moller, S. (1995). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 14:911-922.
21. O'Quigley, J., Shen, L. Z. (1996). Continual reassessment method: a likelihood approach. Biometrics 52:673-684.
22. O'Quigley, J., Pepe, M., Fisher, M. (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
23. O'Quigley, J., Hughes, M., Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57:1018-1029.
24. Potter, D. (2002). Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Statistics in Medicine 21:1805-1823.
25. Relling, M., Dervieux, T. (2001). Pharmacogenetics and cancer therapy. Nature Reviews Cancer 1:99-108.
26. Relling, M., Hancock, M., Rivera, G., Sundlund, J., Ribeiro, R., Krynetski, E., Pui, C. H., Evans, W. (1999). Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Journal of the National Cancer Institute 91:2001-2008.
27. Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R., Porter, A. (2007). Translation of innovative designs into phase I trials. Journal of Clinical Oncology 25(31):4982-4986.
28. Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S., Collins, J., Christian, M. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89:1138-1147.
29. Stallard, N. (2003). Decision-theoretic design for phase II clinical trials allowing for competing studies. Biometrics 59:402-409.
30. Storer, B. (1989). Design and analysis of phase I clinical trials. Biometrics 45:925-937.
31. Thall, P., Russell, K. (1998). A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54:251-264.
32. Thall, P., Estey, E., Sung, H. (1999). A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Investigational New Drugs 17:155-167.
33. Thall, P., Cook, J. (2004). Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60:684-693.
34. Whitehead, J., Brunier, H. (1995). Bayesian decision procedures for dose determing experiments. Statistics in Medicine 14:885-893.
35. Zhou, Y., Whitehead, J., Bonvini, E., Stevens, J. (2006). Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics 5:125-133.